Arthritis drug shows promise against severe COVID: Study

Tofacitinib, taken orally and sold under the brand name Xeljanz among others, was tested in a trial of 289 patients hospitalized with severe COVID across 15 locations in Brazil.

Half received the drug a 10 mg pill twice a day and standard care like glucocorticoids that tamp down an overactive immune response, while the other half received a placebo and standard care.

After 28 days, 18.1 percent of the group receiving the tofacitinib progressed to respiratory failure or death, compared to 29 percent in the placebo group.

This represented a statistically significant relative risk reduction of 63 percent.

Respiratory failure refers to a patient requiring noninvasive ventilation through an oxygen mask, or being intubated and placed on a mechanical ventilator.

Deaths after 28 days occurred in 2.8 percent of patients in the tofacitinib group and in 5.5 percent of those in the placebo group.

Serious side effects occurred in 14.1 percent in the tofacitinib group and in 12 percent in the placebo group.

"We are encouraged by the initial findings of our randomized trial of tofacitinib in patients hospitalized with COVID-19 pneumonia," said Otavio Berwanger of Hospital Israelita Albert Einstein, which coordinated the trial in collaboration with Pfizer.

"These results provide new information which indicates that the use of tofacitinib when added to standard of care, which includes glucocorticoids, may further reduce the risk of death or respiratory failure in this patient population."

Tofacitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors.